NVO
Novo Nordisk A/S Class B · GPW:NVO
156.00 PLN−0.2800 −0.18%
Novo Nordisk A/S Class B (GPW:NVO) last traded at 156.00 PLN, down 0.18% on the day. Over the past year the stock is down 14.31%. Its 52-week range is 129.26 to 230.00. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open156.00
Day range156.00 – 156.00
52-week range129.26 – 230.00
Volume21
Average volume (10 days)79
Market cap (USD)175.64 B
P/E10.38
EPS (TTM) (USD)3.99
Dividend yield4.40%
Beta (1 year)−0.0711
Revenue (TTM) (USD)50.21 B
Employees68.79 K
Performance
+1.96%1 week
+6.83%1 month
−12.44%3 months
−8.36%6 months
−22.77%Year to date
−14.31%1 year
Technical rating
Neutral
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
180.11 PLN
The average 1-year price target, +15.45% from the last price. See the forecast
Latest headlines
- Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.